Summit Therapeutics is trading at $14.20, up 4.26%, with no new September 1, 2026 company-specific announcement or direct catalyst identified.
- Recent investor interest remains linked to positive ivonescimab Phase III results, including the HARMONi-GI1 overall-survival benefit and HARMONi publication; both announcements occurred August 25.
- The gain is occurring despite biotechnology weakness and broader risk-off conditions.
- The move may reflect continued momentum from recent clinical updates rather than a fresh event.